CEO Pascal Soriot knows what’s at stake for AstraZeneca’s business. It is whether China, now the British drugmaker’s second-largest market, can sustain double-digit growth—and some investments that support the Chinese government’s goals are necessary.
In a slew of news coming out of Shanghai on Wednesday, AstraZeneca is teaming up with investment shop China International Capital Corporation to launch a $1 billion fund focused on healthcare, upgrading its Shanghai R&D operations to a global center, establishing a new artificial intelligence innovation center, and partnering up with Sun Pharma to market some oncology drugs in China.
